French university hospital contributing clinical trial sites, pharmacokinetic expertise, and patient cohorts in neuroscience, infectious disease, and regenerative medicine.
CHRU de Tours is a major French university hospital in the Loire Valley that combines clinical care with translational research, particularly in neuroscience, infectious disease, and regenerative medicine. Within EU projects, they contribute clinical trial infrastructure, patient cohorts, and pharmacokinetic expertise — serving as a site where experimental therapies move from lab bench to bedside. Their work spans pediatric neuropsychiatry (ADHD, autism), neurodegenerative disease (ALS), antimicrobial resistance, and bone tissue engineering, reflecting the breadth of a large teaching hospital with multiple specialized departments.
STIPED (brain stimulation for ADHD/autism), AIMS-2-TRIALS (autism biomarkers and clinical outcomes), and Digi-NewB (perinatal neuromonitoring) all center on neurological conditions across the lifespan.
TUDCA-ALS (phase III drug trial for ALS), AB-DiRecT (antibiotic tissue distribution via microdialysis and PBPK/PKPD modeling), and FAIR (phase I immunotherapy trial) all involve advanced clinical pharmacology.
AB-DiRecT focuses on antibiotic distribution in tissue for gonorrhoea and prostatitis, while FAIR addresses drug-resistant pneumonia through immunomodulatory aerosol therapy.
TUDCA-ALS investigates tauroursodeoxycholic acid as a neuroprotective add-on treatment for amyotrophic lateral sclerosis — their largest single grant (EUR 490,906).
ORTHOUNION tests expanded bone marrow mesenchymal stem cells for treating long bone fracture non-union and femoral head necrosis.
Early H2020 participation (2016–2017) focused on pediatric neurodevelopment — brain stimulation therapies for ADHD and autism, perinatal monitoring, and bone regeneration using stem cells. From 2018 onward, the emphasis shifted decisively toward drug-oriented clinical trials: testing neuroprotective compounds for ALS, modeling antibiotic tissue distribution, and running a phase I immunotherapy trial against resistant pneumonia. The trajectory shows a hospital moving from observational and device-based research toward interventional pharmacology and antimicrobial resistance — two areas with strong translational urgency.
CHRU Tours is building capacity in antimicrobial resistance and immunotherapy clinical trials, making them a strong partner for infectious disease drug development projects.
CHRU Tours operates exclusively as a participant or third party — they have never coordinated an H2020 project, which is typical for clinical sites that contribute patient access and trial infrastructure rather than leading research design. They work in large, multinational consortia (115 unique partners across 17 countries), indicating comfort in complex multi-site clinical trials. Their role is that of a reliable clinical partner who brings hospital infrastructure, ethics board access, and patient recruitment to consortia led by others.
Broadly connected across Europe with 115 unique consortium partners spanning 17 countries, reflecting involvement in large multi-center clinical trials. No narrow geographic clustering — their network matches the pan-European distribution typical of health research consortia.
CHRU Tours brings a rare combination of neuropsychiatric and infectious disease clinical trial capabilities within a single institution, covering patient populations from neonates (Digi-NewB) to adults with ALS. Their pharmacokinetic modeling expertise (PBPK/PKPD in AB-DiRecT) adds analytical depth beyond simple trial site services. For consortium builders, they offer a well-connected French university hospital with demonstrated capacity to participate in regulatory-grade clinical trials across multiple therapeutic areas simultaneously.
